patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_750467 | REC_0014901 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 15.5 | 77 | female | 1 | 11 | 5.4 | 2 | osimertinib 80 mg daily | 22.3 | true | MSS | 2026-03-15T05:36:00.963108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333587 | REC_0014902 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.3 | 63 | male | 0 | 4 | 5.9 | 8 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:00.963510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664308 | REC_0014903 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 7.3 | 58 | female | 0 | 32 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:36:00.963905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754356 | REC_0014904 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 7.6 | 59 | female | 0 | 10 | 5.3 | 2 | entrectinib 600 mg daily | 29.2 | false | MSS | 2026-03-15T05:36:00.964470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340082 | REC_0014905 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.4 | 71 | female | 1 | 10 | 6.3 | 5 | sotorasib 960 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:36:00.964903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181674 | REC_0014906 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 17.4 | 72 | female | 1 | 12 | 5.7 | 2 | sotorasib 960 mg daily | 15.3 | true | MSI-H | 2026-03-15T05:36:00.965302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529443 | REC_0014907 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 13.6 | 51 | female | 0 | 11 | 5.2 | 1 | osimertinib 80 mg daily | 16.2 | true | MSS | 2026-03-15T05:36:00.965761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487189 | REC_0014908 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.7 | 73 | female | 2 | 9 | 4.2 | 6 | osimertinib 80 mg daily | 8.7 | false | MSS | 2026-03-15T05:36:00.966166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484871 | REC_0014909 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 9.5 | 65 | female | 1 | 15 | 4.3 | 2 | entrectinib 600 mg daily | 21.3 | true | MSS | 2026-03-15T05:36:00.966527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778273 | REC_0014910 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 13.7 | 76 | female | 1 | 18 | 5.1 | 0 | sotorasib 960 mg daily | 20.3 | true | MSI-H | 2026-03-15T05:36:00.966865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801736 | REC_0014911 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13 | 61 | male | 0 | 16 | 4.8 | 4 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:36:00.967227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132696 | REC_0014912 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.4 | 58 | female | 1 | 14 | 5.2 | 4 | osimertinib 80 mg daily | 10 | false | MSI-H | 2026-03-15T05:36:00.967793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263415 | REC_0014913 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 17.2 | 82 | female | 3 | 14 | 5 | 1 | osimertinib 80 mg daily | 24.8 | true | MSI-H | 2026-03-15T05:36:00.968407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624867 | REC_0014914 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.5 | 60 | female | 0 | 24 | 5.8 | 5 | entrectinib 600 mg daily | 11 | true | MSS | 2026-03-15T05:36:00.968941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485949 | REC_0014915 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 9.7 | 61 | female | 0 | 18 | 5.2 | 7 | entrectinib 600 mg daily | 7 | true | MSS | 2026-03-15T05:36:00.969393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639837 | REC_0014916 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 12.5 | 66 | female | 1 | 13 | 3.5 | 0 | osimertinib 80 mg daily | 23.6 | true | MSI-H | 2026-03-15T05:36:00.969799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760648 | REC_0014917 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.8 | 62 | female | 0 | 17 | 5.2 | 3 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:36:00.970207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122933 | REC_0014918 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.9 | 69 | female | 1 | 7 | 8.3 | 2 | alectinib 600 mg BID | 25.7 | true | MSS | 2026-03-15T05:36:00.970602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365709 | REC_0014919 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.9 | 72 | female | 2 | 8 | 7.3 | 4 | osimertinib 80 mg daily | 16.8 | true | MSS | 2026-03-15T05:36:00.970953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648927 | REC_0014920 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 14.9 | 60 | male | 1 | 11 | 8.1 | 4 | alectinib 600 mg BID | 10.3 | false | MSI-H | 2026-03-15T05:36:00.971372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975312 | REC_0014921 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 35 | 9.1 | 71 | female | 1 | 22 | 4.8 | 6 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:36:00.971766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380154 | REC_0014922 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 6.7 | 72 | female | 2 | 22 | 6.7 | 5 | alectinib 600 mg BID | 9.3 | true | MSS | 2026-03-15T05:36:00.972265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703367 | REC_0014923 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 7.8 | 71 | female | 1 | 9 | 7.5 | 1 | osimertinib 80 mg daily | 26 | false | MSS | 2026-03-15T05:36:00.972658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858724 | REC_0014924 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.1 | 73 | female | 1 | 12 | 6.5 | 5 | alectinib 600 mg BID | 19.7 | false | MSI-H | 2026-03-15T05:36:00.973029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966678 | REC_0014925 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 12.2 | 59 | female | 0 | 3 | 5.5 | 0 | osimertinib 80 mg daily | 35.2 | true | MSS | 2026-03-15T05:36:00.973594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601277 | REC_0014926 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 15.9 | 83 | male | 2 | 9 | 4.2 | 1 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:36:00.974038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239915 | REC_0014927 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5 | 62 | female | 0 | 18 | 4.9 | 5 | pembrolizumab 200 mg q3w | 9.9 | false | MSS | 2026-03-15T05:36:00.974412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875685 | REC_0014928 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 8 | 57 | female | 1 | 20 | 6.6 | 5 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:00.974799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496972 | REC_0014929 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 13.7 | 65 | male | 0 | 14 | 6.5 | 1 | sotorasib 960 mg daily | 10 | false | MSS | 2026-03-15T05:36:00.975199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599571 | REC_0014930 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9.1 | 63 | female | 1 | 17 | 5.9 | 1 | sotorasib 960 mg daily | 23.7 | false | MSS | 2026-03-15T05:36:00.975601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397690 | REC_0014931 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 10.7 | 68 | female | 0 | 9 | 7.3 | 1 | sotorasib 960 mg daily | 14.9 | true | MSS | 2026-03-15T05:36:00.975974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837975 | REC_0014932 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.9 | 70 | female | 1 | 10 | 6.9 | 7 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:36:00.976415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500405 | REC_0014933 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 5.5 | 70 | male | 0 | 10 | 6.5 | 3 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:36:00.976800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851614 | REC_0014934 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 7.7 | 65 | female | 0 | 6 | 4.8 | 0 | osimertinib 80 mg daily | 24.6 | false | MSS | 2026-03-15T05:36:00.977163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838831 | REC_0014935 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.1 | 70 | female | 2 | 15 | 5.1 | 1 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.977518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808130 | REC_0014936 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 10.2 | 61 | male | 1 | 7 | 5.3 | 1 | alectinib 600 mg BID | 19.3 | false | MSI-H | 2026-03-15T05:36:00.977878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646703 | REC_0014937 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.8 | 63 | male | 0 | 7 | 4.2 | 6 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:36:00.978217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729714 | REC_0014938 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.1 | 68 | female | 1 | 24 | 6 | 5 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:36:00.978735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546884 | REC_0014939 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.1 | 66 | female | 0 | 53 | 5 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:36:00.979161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711382 | REC_0014940 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.4 | 71 | female | 3 | 56 | 6 | 3 | pembrolizumab 200 mg q3w | 17.2 | false | MSS | 2026-03-15T05:36:00.979552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199402 | REC_0014941 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.7 | 73 | female | 2 | 19 | 4.5 | 6 | entrectinib 600 mg daily | 5.2 | false | MSI-H | 2026-03-15T05:36:00.979933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406437 | REC_0014942 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12.6 | 70 | female | 1 | 6 | 5.9 | 2 | entrectinib 600 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:36:00.980446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671947 | REC_0014943 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 10.3 | 68 | female | 1 | 14 | 5.8 | 1 | pembrolizumab 200 mg q3w | 17.7 | true | MSS | 2026-03-15T05:36:00.980834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405381 | REC_0014944 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 12.8 | 54 | male | 0 | 16 | 4.8 | 1 | pembrolizumab 200 mg q3w | 6.7 | true | MSS | 2026-03-15T05:36:00.981237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396243 | REC_0014945 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.6 | 74 | female | 1 | 12 | 6.2 | 7 | osimertinib 80 mg daily | 6.1 | true | MSS | 2026-03-15T05:36:00.981605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435831 | REC_0014946 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.8 | 63 | female | 1 | 16 | 6.2 | 7 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:36:00.982314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411384 | REC_0014947 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 6.2 | 75 | male | 1 | 31 | 6.8 | 5 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:36:00.982783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129547 | REC_0014948 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 16.8 | 61 | male | 1 | 6 | 6.4 | 4 | sotorasib 960 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:36:00.983200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817441 | REC_0014949 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.8 | 69 | female | 1 | 12 | 3.7 | 5 | alectinib 600 mg BID | 4.2 | false | MSI-H | 2026-03-15T05:36:00.983596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239019 | REC_0014950 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 10.2 | 90 | female | 2 | 3 | 7 | 2 | alectinib 600 mg BID | 16.1 | false | MSS | 2026-03-15T05:36:00.983975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189258 | REC_0014951 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 16.7 | 71 | female | 1 | 13 | 5.5 | 7 | pembrolizumab 200 mg q3w | 10.7 | true | MSI-H | 2026-03-15T05:36:00.984647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557917 | REC_0014952 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 9.4 | 67 | male | 0 | 17 | 3.4 | 0 | sotorasib 960 mg daily | 35.5 | true | MSS | 2026-03-15T05:36:00.985090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409205 | REC_0014953 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.7 | 82 | female | 2 | 26 | 2.5 | 5 | sotorasib 960 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:36:00.985535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926343 | REC_0014954 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5 | 75 | female | 2 | 94 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.1 | false | MSS | 2026-03-15T05:36:00.985956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112952 | REC_0014955 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.9 | 69 | female | 1 | 20 | 4.5 | 4 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:36:00.986366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475191 | REC_0014956 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 11.8 | 71 | female | 1 | 3 | 6.4 | 2 | alectinib 600 mg BID | 20.4 | true | MSS | 2026-03-15T05:36:00.986761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100852 | REC_0014957 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 2.2 | 69 | female | 0 | 4 | 6.1 | 2 | alectinib 600 mg BID | 17.6 | false | MSS | 2026-03-15T05:36:00.987119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248359 | REC_0014958 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.9 | 66 | female | 0 | 22 | 7.6 | 2 | pembrolizumab 200 mg q3w | 11.1 | false | MSI-H | 2026-03-15T05:36:00.987474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652347 | REC_0014959 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 37 | 12.8 | 68 | female | 0 | 19 | 6.6 | 0 | alectinib 600 mg BID | 60.1 | true | MSS | 2026-03-15T05:36:00.987845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271701 | REC_0014960 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.5 | 66 | female | 1 | 17 | 4.9 | 1 | pembrolizumab 200 mg q3w | 21.5 | false | MSS | 2026-03-15T05:36:00.988364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245525 | REC_0014961 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 12.7 | 72 | female | 1 | 19 | 3.7 | 1 | alectinib 600 mg BID | 23.9 | false | MSS | 2026-03-15T05:36:00.988777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960912 | REC_0014962 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.6 | 68 | female | 1 | 73 | 6.1 | 1 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:36:00.989548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574959 | REC_0014963 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 5.5 | 66 | male | 1 | 16 | 5.6 | 5 | entrectinib 600 mg daily | 16 | false | MSS | 2026-03-15T05:36:00.990016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589861 | REC_0014964 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 16.5 | 61 | female | 0 | 20 | 7.1 | 2 | osimertinib 80 mg daily | 26.1 | false | MSS | 2026-03-15T05:36:00.990597+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768628 | REC_0014965 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.8 | 67 | male | 1 | 26 | 2.4 | 7 | sotorasib 960 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:00.991044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570693 | REC_0014966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 14 | 75 | female | 2 | 12 | 6 | 2 | alectinib 600 mg BID | 6.7 | false | MSI-H | 2026-03-15T05:36:00.991471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660565 | REC_0014967 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.4 | 59 | female | 0 | 15 | 5.4 | 6 | osimertinib 80 mg daily | 9 | true | MSI-H | 2026-03-15T05:36:00.991875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358121 | REC_0014968 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 13.9 | 57 | male | 1 | 22 | 5.4 | 2 | osimertinib 80 mg daily | 21.8 | false | MSI-H | 2026-03-15T05:36:00.992328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834821 | REC_0014969 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.8 | 57 | female | 1 | 13 | 5.7 | 8 | sotorasib 960 mg daily | 10.7 | false | MSS | 2026-03-15T05:36:00.992735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621940 | REC_0014970 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.5 | 63 | female | 1 | 17 | 4.1 | 3 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:36:00.993110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820050 | REC_0014971 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11 | 51 | female | 0 | 19 | 7 | 1 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:36:00.993491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960353 | REC_0014972 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 17.8 | 72 | female | 1 | 19 | 5.4 | 2 | alectinib 600 mg BID | 24.3 | true | MSS | 2026-03-15T05:36:00.993866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665783 | REC_0014973 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 2.2 | 63 | male | 0 | 11 | 5.6 | 6 | pembrolizumab 200 mg q3w | 12.1 | false | MSS | 2026-03-15T05:36:00.994230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408325 | REC_0014974 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.9 | 65 | male | 0 | 19 | 5.5 | 2 | alectinib 600 mg BID | 18.4 | false | MSS | 2026-03-15T05:36:00.994609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808175 | REC_0014975 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.6 | 76 | male | 2 | 52 | 7.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:36:00.994999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581492 | REC_0014976 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 27 | 4.6 | 67 | female | 0 | 3 | 6.6 | 0 | pembrolizumab 200 mg q3w | 40.2 | false | MSS | 2026-03-15T05:36:00.995399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609619 | REC_0014977 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 5 | 71 | female | 1 | 22 | 5 | 2 | alectinib 600 mg BID | 9.4 | true | MSS | 2026-03-15T05:36:00.995938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453500 | REC_0014978 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 8.9 | 63 | male | 0 | 9 | 3.5 | 6 | alectinib 600 mg BID | 14.7 | true | MSS | 2026-03-15T05:36:00.996498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711074 | REC_0014979 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 37 | 10.9 | 80 | female | 0 | 13 | 6.3 | 6 | alectinib 600 mg BID | 24.9 | true | MSI-H | 2026-03-15T05:36:00.996896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943869 | REC_0014980 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 2.7 | 59 | male | 0 | 58 | 3.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | true | MSS | 2026-03-15T05:36:00.997240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203098 | REC_0014981 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 12.4 | 73 | female | 1 | 24 | 8.2 | 2 | osimertinib 80 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:36:00.997560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466325 | REC_0014982 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.2 | 72 | male | 1 | 17 | 5.1 | 2 | entrectinib 600 mg daily | 18.6 | false | MSI-H | 2026-03-15T05:36:00.997859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938157 | REC_0014983 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4.5 | 71 | male | 2 | 54 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.9 | true | MSS | 2026-03-15T05:36:00.998446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230552 | REC_0014984 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 14.6 | 71 | female | 2 | 13 | 6.5 | 7 | entrectinib 600 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:36:00.998932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847234 | REC_0014985 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 15.1 | 68 | female | 1 | 11 | 6.4 | 2 | osimertinib 80 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:36:00.999352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104622 | REC_0014986 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 9.3 | 72 | female | 2 | 7 | 5 | 1 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:36:00.999777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379536 | REC_0014987 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 18.9 | 54 | female | 0 | 16 | 5.1 | 6 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:36:01.000253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676985 | REC_0014988 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 5.3 | 74 | female | 1 | 5 | 3.2 | 8 | entrectinib 600 mg daily | 14.8 | false | MSS | 2026-03-15T05:36:01.000687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524049 | REC_0014989 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.2 | 90 | female | 1 | 40 | 6.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSS | 2026-03-15T05:36:01.003031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463007 | REC_0014990 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 20.5 | 54 | male | 0 | 17 | 4.1 | 1 | entrectinib 600 mg daily | 19.8 | true | MSI-H | 2026-03-15T05:36:01.003848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797543 | REC_0014991 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.3 | 68 | male | 1 | 51 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.9 | false | MSS | 2026-03-15T05:36:01.004422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124340 | REC_0014992 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 18.7 | 53 | female | 0 | 13 | 5.6 | 4 | sotorasib 960 mg daily | 16 | false | MSS | 2026-03-15T05:36:01.004860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840629 | REC_0014993 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13 | 81 | female | 1 | 19 | 3 | 1 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:01.005259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815629 | REC_0014994 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.5 | 62 | male | 1 | 4 | 5.1 | 2 | pembrolizumab 200 mg q3w | 21.6 | false | MSS | 2026-03-15T05:36:01.005616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164334 | REC_0014995 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.8 | 81 | female | 3 | 58 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:36:01.005986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692089 | REC_0014996 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.1 | 50 | female | 0 | 8 | 6.8 | 5 | sotorasib 960 mg daily | 11.4 | true | MSS | 2026-03-15T05:36:01.006365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616442 | REC_0014997 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 17.4 | 66 | female | 1 | 20 | 6.9 | 2 | sotorasib 960 mg daily | 8.8 | true | MSS | 2026-03-15T05:36:01.006736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887610 | REC_0014998 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.4 | 62 | male | 1 | 17 | 6.8 | 1 | osimertinib 80 mg daily | 18 | false | MSI-H | 2026-03-15T05:36:01.007110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503447 | REC_0014999 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 6.2 | 73 | female | 0 | 38 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:36:01.007485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605109 | REC_0015000 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 9.6 | 67 | male | 1 | 14 | 3.5 | 7 | sotorasib 960 mg daily | 4.2 | false | MSS | 2026-03-15T05:36:01.007844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.